Drug Candidates for the Treatment of Alzheimer’s and Parkinson’s Disease
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Medicinal Chemistry".
Deadline for manuscript submissions: closed (30 September 2022) | Viewed by 6981
Special Issue Editors
Interests: drug design for neurodegenerative diseases; multi-target directed ligands; multifunctional ligands; anti-neuroinflammatory drug candidates and neuroprotection; inflammation; pain; cancer; neglected diseases; psychiatric diseases
Interests: neuroprotection; Parkinson’s disease; Huntington’s disease; neurodegenerative diseases
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
During the last three decades, neurodegenerative diseases and dementia, especially Alzheimer’s (AD) and Parkinson’s (PD) diseases, have been recognized as some of the most challenging issues for medicinal chemistry, pharmacology, and all other health- and drug-related sciences, due to their multifactorial and complex pathophysiology, severity, high social–economic impacts. With longevity being one of the most important risk factors, all available statistical data agree that in the coming three decades, as the world population becomes older, the number of patients with one of these incapacitant diseases will reach an exponential increase unless we are able to discover novel disease-modifying drugs or effective cures. In this context, a great number of scientists working in academia and the pharma industry have dedicated their efforts to the design, synthesis, and evaluation of new small molecules that could act as genuine and innovative drug candidates addressed to the multifactorial-related biochemical and cellular changes related to the onset, progression and severity of neurodegeneration. Thus, the aim of this Special Issue is to collect high-impact scientific contributions, representing the most outstanding up-to-date results and new findings related to the discovery of novel chemical entities with potential druggability and therapeutical value for the treatment of AD and PD.
Dr. Cláudio Viegas-Junior
Prof. Dr. Andrea Tarozzi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- Parkinson’s disease
- multitarget directed ligands
- multifunctional ligands
- neurodegeneration
- neuroinflammation
- neuroprotection
- neurodegenerative diseases
- brain disorders
- dementia
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.